Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 30 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

N/A

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedSep 29

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

Contacts1 person available

OfficeUSA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health

Office AddressUSA

Contacts

NIA Scientific Program Contact

contact@example.gov

Full Description

Show more

The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose early to definitive clinical trials. Trials testing drugs, devices, biologics, procedures, behavioral, social, economic, health services, or other biomedical or non-pharmacological interventions are of interest to this initiative. The trials should align with the research mission of the participating Institutes, Centers, and Offices (ICOs) of the NIH.

The NOFO will utilize the R61/R33 activity code, a bi-phasic, milestone-driven award. The R61 phase provides support for planning activities, and the R33 phase provides support for a clinical trial, with a maximum project period of 7 years.

Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and relevant projects. Investigators with expertise in clinical trial planning, design, implementation, intervention development, and/or stakeholder engagement are encouraged to consider applying for the NOFO.

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

Continuation of the Exceptional Longevity Data Management and Coordinating Center (EL DMCC) (U24 Clinical Trial Not Allowed)The National Institute on Aging intends to issue a single U24 cooperative agreement award to support the continued operation and expansion of the Exceptional Longevity Data Management and Coordinating Center. Serving as the central hub for human longevity translational research, the center integrates deeply phenotyped cohorts and multi-omics datasets to enable cross-cohort analyses and collaborative research. Key responsibilities include data harmonization, the implementation of common data standards, and the management of the ELITE Portal, which provides the research community with secure access to analytical tools and cloud-based computational workspaces. The upcoming funding opportunity will require the Coordinating Center to expand its capabilities in artificial intelligence, machine learning, and the integration of diverse datasets across different species. Future objectives include the development of curated target knowledgebases for therapeutic targets, the enhancement of portal interoperability according to FAIR data principles, and the strengthening of community engagement through specialized training and workshops. This notice serves as a forecast to allow potential applicants to establish collaborations before the official solicitation is released.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Immune Drivers of Autoimmune DiseaseThe National Institute of Allergy and Infectious Diseases seeks to support the Immune Drivers of Autoimmune Disease network to investigate the triggers and early mechanisms of autoimmunity in humans. The primary goal is to develop tools for risk prediction and staging, identify pre-clinical immune mechanisms, and utilize artificial intelligence and big data to prevent autoimmune diseases. This initiative emphasizes the creation of preclinical cohorts and the use of remote recruitment and sampling to advance medical research. The network will be managed by a Coordinating Center responsible for data harmonization, sample sharing, and the administration of an Infrastructure Opportunity Fund for collaborative research projects. This forecast, issued by the National Institutes of Health under the Department of Health and Human Services, establishes a framework for shared infrastructure and steering committee oversight to identify common pathways and prevention opportunities.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)The National Institutes of Health, through the Department of Health and Human Services, is soliciting applications for the NLM Grants for Scholarly Works in Biomedicine and Health program. This initiative provides funding for the creation of book-length manuscripts and other integrative scholarly works, such as critical reviews and analytical syntheses, designed to benefit U.S. health professionals, scientists, and public health practitioners. The primary goal is to organize and disseminate biomedical and health-related knowledge to improve research, education, and clinical practice. This opportunity is listed as a forecast with a posted date of September 24, 2026. It specifically prohibits the use of clinical trials. Interested parties can contact the NLM Extramural Programs office for further information regarding the application process and program requirements.

Book Publishers

POSTED

DEADLINE

Partnerships for Advancing Development of Diagnostics for Infectious DiseasesThe National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking to establish partnerships between academic or small business investigators and industrial partners to advance the translational development of diagnostic tests for infectious diseases. This initiative focuses on moving diagnostics that have already demonstrated proof-of-concept through the commercialization process by aligning researchers with experienced industry partners to de-risk development and ensure products are fit for purpose. The program will be supported by a science advisory board and NIAID oversight, incorporating annual meetings and workshops to facilitate collaboration and knowledge exchange. This effort is authorized under the Public Health Service Act and federal regulations to ensure that promising diagnostic technologies are successfully translated into tools for treating and preventing infectious diseases.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE)The National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting the LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE) program. This initiative aims to bridge the gap between traditional clinical trial findings and real-world application by supporting collaborations on effectiveness trials, pragmatic trials, and hybrid effectiveness-implementation studies. The program focuses on the prevention and treatment of HIV, including associated coinfections and comorbidities, across all age groups and various points of care. The goal of the program is to advance cross-cutting research in epidemiology, implementation science, and clinical, behavioral, and social sciences. This effort aligns with the broader NIH mission to implement research advances in HIV/AIDS. The opportunity is authorized under the Public Health Service Act and relevant federal regulations, with administrative oversight provided by the Division of AIDS Epidemiology Branch.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Collaborative Centers in Children’s Environmental Health Research and Translation (P2C Clinical Trial Optional)The National Institutes of Health, under the Department of Health and Human Services, is seeking applications to establish a national network of Children's Environmental Health Research Translation Centers. These centers are designed to protect and improve children's health by developing scientific questions and public health interventions focused on translational research. A primary objective is to move evidence-informed biomedical findings into practical application for the wider community while mentoring a new generation of investigators in the field. Beyond research and translation, the program will function as a national resource to coordinate responses to emerging environmental exposures that impact children. The initiative emphasizes the creation of actionable strategies to prevent harm and ensure a healthy future for children through collaborative efforts within the environmental health community.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

The Role of the Innate Immune System in the Pathogenesis of Type 1 DiabetesThe National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, is forecasting a grant opportunity to investigate the role of the innate immune system in the initiation of Type 1 Diabetes. Funded by the Special Statutory Funding Program for Type 1 Diabetes Research, this initiative seeks to identify genetic and environmental causes of the disease by examining how innate immune components interact with beta cells and pancreatic tissues. The program emphasizes the use of new approach methodologies to determine the timing and impact of environmental triggers that activate these immune pathways. The primary objective is to improve the early identification of high-risk individuals and develop future prevention and therapeutic strategies. This effort is conducted under the authority of the Public Health Service Act and relevant federal regulations. Interested parties can contact the RISP-T1D point of contact for further information regarding this forecast.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)The National Institute of Neurological Disorders and Stroke (NINDS) is seeking to support scientific research using data from intermediate-size patient population expanded access protocols for Amyotrophic Lateral Sclerosis (ALS). To be eligible, protocols must provide access to an investigational drug or biological product for individuals with ALS and generate data that supports research into the prevention, diagnosis, mitigation, treatment, or cure of the disease. Research goals may include analyzing the effects of products on biomarkers, target engagement, safety and outcome information such as survival and hospitalization, or general patient experience data. This opportunity is currently listed as a forecast by the National Institutes of Health under the Department of Health and Human Services, and applications are not being solicited at this time. The notice serves as a preliminary announcement to allow potential applicants sufficient time to develop responsive projects. Interested parties can contact the ALS Program for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Research to Improve Rigor, Replicability, and Reproducibility in Biomedical and Behavioral SciencesThe National Institute of Neurological Disorders and Stroke, in collaboration with other NIH entities, is forecasting support for research projects aimed at enhancing biomedical and behavioral rigor, replicability, and reproducibility. Key areas of interest include assessing the scientific impact of these improvements, creating frameworks for selecting high-value replication studies, and measuring the robustness and generalizability of research findings to drive scientific innovation. This notice serves as a forecast to allow potential applicants to establish collaborations and develop responsive projects, as formal applications are not currently being solicited. Interested parties can contact the NINDS Office of Research Quality for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)The National Institutes of Health, through the National Institute of Mental Health, is issuing a forecast for a Notice of Funding Opportunity titled Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs). This initiative aims to establish a research network to evaluate the clinical effectiveness, safety, and durability of rapid-acting treatments such as ketamine, esketamine, and psilocybin for individuals with serious mental illnesses. The primary objective is to generate actionable real-world evidence to determine how these interventions can be safely and sustainably integrated into routine clinical practice across diverse patient populations and healthcare settings. By addressing current gaps in knowledge regarding implementation and long-term benefits, the project seeks to inform future healthcare delivery strategies for emerging psychotropic treatments.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Emerging Global Leader Award (K43)The Emerging Global Leader Award (K43), issued by the National Institutes of Health under the Department of Health and Human Services, provides salary and research support to junior faculty and research scientists based at academic or research institutions in Low- and Middle-Income Countries. The program focuses on biomedical, behavioral, and clinical research that leverages unique opportunities in these regions to create generalizable knowledge benefiting both U.S. and international populations. Recipients must engage in intensive mentored research and career development guided by senior researchers from both the U.S. and their respective home countries. By leveraging existing NIH research investments, the initiative aims to develop global research leaders who can mentor future investigators and strengthen international research networks.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Single Source: Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Data Resource and Administrative Coordination Center (U24 Clinical Trial Not Allowed)The National Institute of Mental Health intends to issue a single-source cooperative agreement to the University of California, Santa Cruz, to renew the Data Resource and Administrative Coordination Center within the SSPsyGene Consortium. The primary objective is to study how risk genes for neurodevelopmental and psychiatric disorders influence biological systems across molecular, cellular, and organismal levels. The renewed center will focus on creating a sustainable, interoperable knowledge base with standardized data terms to facilitate the use of artificial intelligence in accelerating brain function research for the broader biomedical community. This opportunity is currently listed as a forecast for a single source Notice of Funding Opportunity. While the award is intended for a specific institution, applications will still undergo the standard NIH peer-review process to ensure only meritorious projects are funded. The initiative emphasizes the harmonization of data from Assay and Data Generation Centers and the improvement of submission processes to data archives.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS